completely agreed, licensing agreement would be best news...

Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #

First 88 Last

Share
Profile

Follow
Rickadonski

85 Posts.

37

09/06/22

17:11

Post #: 61924516
Share

Originally posted by rustys33: ↑

I think there is too large a gap between what the owners of RAP are prepared to part ways for and what Pfizer are currently willing to pay.....this is the nature of blue sky investing meeting conservative corporate culture. If you were a Pfizer employee, you don't want to stake your career on something that my fail, as the upside doesn't offset the downside. Us investors stake our cash, but their is no reputational risk for backing a donkey.

That said, Pfizer want Covid diagnosis ASAP. A takeover would've been the fastest and simplest way to accomplish this both from a resourcing and approval perspective. RAP/Pfizer now return to the drawing board and need to come up with a plan to bring covid diagnosis to market ASAP. My guess is that the takeover bid is off the table and an extended product licensing agreement to get the product to market will be announced. These next steps, milestones and costings are what are being determined as we wait.

This explains;

- Phone calls assessing how much it would cost to acquire RAP
- Continued presentations by RAP at investor forums
- $4 million up front payment to continue covid diagnosis
- Length on trading suspension

Expand

completely agreed, licensing agreement would be best news possible and would put an absolute rocket up the SP

RAP Price at posting: 11.0¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

CC9

Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20%

FFM

Firefly positioned for copper growth in Canada ahead of resource update

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia